Cargando…

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer

BACKGROUND: Cetuximab and panitumumab are monoclonal antibodies targeting the epidermal growth factor receptor. Both drugs are active against RAS wild type metastatic colorectal cancer after chemotherapy failure, with similar efficacy and toxicity profiles. However, their cost and limited survival b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalho, Adriana Camargo, Leal, Frederico, Sasse, Andre Deeke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389795/ https://www.ncbi.nlm.nih.gov/pubmed/28403233 http://dx.doi.org/10.1371/journal.pone.0175409

Ejemplares similares

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
por: Kasagi, Yuta, et al.
Publicado: (2013)

Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
por: Krawczyk, Paweł Adam, et al.
Publicado: (2013)

Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: da Silva, Wânia Cristina, et al.
Publicado: (2018)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
por: García-Foncillas, Jesús, et al.
Publicado: (2019)

Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis
por: Leal, Frederico, et al.
Publicado: (2015)

The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients
por: Tang, Xue-Miao, et al.
Publicado: (2017)

Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution
por: SONODA, HIROMICHI, et al.
Publicado: (2013)

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
por: Yazdi, Mohammad Hossein, et al.
Publicado: (2015)

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab
por: Odom, Dawn, et al.
Publicado: (2010)

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report
por: MEKATA, EIJI, et al.
Publicado: (2013)

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab
por: Xu, Yifan, et al.
Publicado: (2018)

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups
por: Macedo, Ligia Traldi, et al.
Publicado: (2012)

Patient considerations in metastatic colorectal cancer – role of panitumumab
por: Rogers, Jane E
Publicado: (2017)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
por: López-Gómez, Miriam, et al.
Publicado: (2012)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis
por: Zhou, Si-wei, et al.
Publicado: (2012)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
por: Watanabe, Shoichi, et al.
Publicado: (2017)

Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
por: TSUKIHARA, HIROSHI, et al.
Publicado: (2015)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
por: Bouché, Olivier, et al.
Publicado: (2019)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
por: Jin, Haoxing D., et al.
Publicado: (2020)

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
por: Price, Timothy, et al.
Publicado: (2020)

The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis
por: Chen, Qiang, et al.
Publicado: (2016)

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
por: Pathak, Surajit, et al.
Publicado: (2017)

An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer
por: Poulin-Costello, Melanie, et al.
Publicado: (2013)

Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer
por: Koumaki, Dimitra, et al.
Publicado: (2020)

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
por: Braig, Friederike, et al.
Publicado: (2015)

Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Lima, André Bacellar Costa, et al.
Publicado: (2011)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016)

Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market
por: Davari, Majid, et al.
Publicado: (2015)

EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis
por: Jiang, Zheng, et al.
Publicado: (2013)

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
por: Jia, Jingquan, et al.
Publicado: (2018)

Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer
por: Ma, Jian, et al.
Publicado: (2017)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer
por: Yokokawa, Hideyuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_61bh7nh1e5utmbc60t1tlh1ejj